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Abstract 
Medical abortion is a method of pregnancy termination that by its nature enables more active 
involvement of women in the process of managing, and sometimes even administering the 
medications, for their abortions. This qualitative evidence synthesis reviewed the global evidence on 
experiences with, preferences for, and concerns about greater self-management of medical abortion 
with lesser health professional involvement.  We focused on qualitative research from multiple 
perspectives on women’s experiences of self-management of first trimester medical abortion (<12 
weeks) gestation. We included research from both legal and legally-restricted contexts whether 
medical abortion was accessed through formal or informal systems. A review team of four identified 
36 studies meeting inclusion criteria, extracted data from these studies, and synthesized review 
findings. Review findings were organized under the following themes: general perceptions of self-
management, preparation for self-management, logistical considerations, issues of choice and 
control, and meaning and experience. The synthesis highlights that the qualitative evidence base is 
still small, but that the available evidence points to the overall acceptability of self-administration of 
medical abortion. We highlight particular considerations when offering self-management options, 
and identify key areas for future research. Further qualitative research is needed to strengthen this 
important evidence base.  
 
Introduction and Background 
Medical abortion is a method of pregnancy termination that enables more active involvement of 
women in the process of managing, and sometimes even administering the medication for, their 
abortions. We define self-management as the overall management of the medical abortion process 
when one or more aspects of the process occurs outside of a clinical context. We also use the term 
self-administration to refer to a specific aspect of self-management, the act of taking the medication 
(mifepristone, misoprostol -also known as Cytotec- or both) outside a clinical context without clinical 
supervision. Enabling women’s greater self-management of their abortions is one way of improving 
access to safe abortion by lessening demand on the health system, and by overcoming geographical 
and financial barriers to accessing health facilities. However, concerns remain around what forms of 
self-management are safe, effective, feasible and acceptable. In relation to feasibility and 
acceptability, this qualitative evidence synthesis (also known as a systematic review of qualitative 
research) reviewed the global evidence on experiences with, preferences for, and concerns about 
greater self-management of medical abortion with lesser health professional involvement. The aim 
of the paper is to synthesize the global evidence on self-management.   
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Existing protocols for medical abortion—and the options for self-management in the protocol—vary 
widely. In the majority of settings described in the qualitative literature we reviewed, where 
abortion was being legally-provided, the organisation of medical abortion care was rooted in a 
medicalized, three-clinic-visit model: a first visit to initiate the abortion process, receive counselling 
and take mifepristone, a second visit generally two days later to take or be given misoprostol, and a 
follow-up visit 1-2 weeks later to confirm completion of the abortion. Current WHO guidelines for 
medical abortion offer guidance for enabling women to take mifepristone at the clinic and receive 
misoprostol from a healthcare provider to self-administer at home, assuming that appropriate 
counselling is provided, and follow-up and emergency care are accessible. However, the three-clinic-
visit model is the dominant model in highly medicalized settings. [1] 
We draw on a ‘medicalization’ framework [2] [3] to describe the spectrum of approaches to the 
management of medical abortion ranging from most medicalized to least medicalized. Shifts towards 
less medicalized care can include: the administration of misoprostol in clinic but the option for 
women to be discharged to manage the process of expulsion at home[4] [5]; the option to self-
administer misoprostol at home after the clinical administration of mifepristone [6] [7]; the option to 
administer both misoprostol and mifepristone at home; and replacing follow-up with remote 
monitoring/self-assessment of abortion completion, for example via mobile phones [8], or the 
independent use of self-assessment cards and pregnancy tests. [9] [10] 
In this review, we focused exclusively on first-trimester medical abortion. Although the cut-off 
between first trimester and second trimester medical abortion is somewhat arbitrary, it is a 
politically, experientially and medically important distinction. As second trimester medical abortion 
implies both changes in the route, timing and dosage of the medication [11] and increased risk 
associated with gestational age, women may have additional needs for professional and mentoring 
support. [12].  
This synthesis was one of several carried out to inform the 2015 World Health Organization guideline 
entitled “Health Worker Roles in Providing Safe Abortion Care.” [12]. The guideline acknowledges 
that, “…it is possible for women to play a role in managing some of the components by themselves 
outside of a health-care facility” [12,p41] and centres them as important actors in their medical 
abortions. 
 
Methods 
Search Strategy 
We searched the following electronic databases for eligible studies: MEDLINE, CINAHL Plus, WHO 
Global Health Library, Global Health and Popline. Bibliographies and grey literature were also 
searched. The original search for the WHO guideline [12] was up to June 23, 2014. For publication, 
we updated our searches through to October 27, 2015. The PRISMA diagram (Figure 1) represents 
the search and inclusion (combining original and updated searches). We considered studies in 
English, Spanish, Portuguese, and French for inclusion.  
[Figure 1 approximately here] 
Study Selection  
Our primary inclusion criteria were that the study report either on the experiences of women self-
managing their medical abortions in some way or on perspectives (current or future) about self-
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management. We included studies reporting the perspectives of women, their partners, family 
members, health professionals, programme managers or policymakers. As is common in qualitative 
evidence synthesis (QES), our inclusion and exclusion criteria were revised as we read through all the 
abstracts and reached consensus on the criteria [13]. At the start of the selection process, the four 
authors independently assessed the first 200 abstracts. They then discussed the studies selected for 
inclusion and clarified the inclusion criteria. MW then reviewed all the abstracts and AS and NL each 
reviewed half the abstracts, ensuring all abstracts were screened by two reviewers. Full texts of 
papers identified as “potentially relevant” were retrieved and assessed for inclusion. Disagreements 
were resolved through discussion. Inclusion criteria were revised and clarified throughout this stage 
in response to the emerging evidence. 
A key decision was the inclusion of data from settings where abortion was legally restricted, deemed 
as “indirectly relevant”. According to Lewin et al, “the evidence supporting a review finding may be 
indirectly relevant if one of the review domains above, such as perspective or setting, has been 
substituted with another” [14,p7]. In this case, evidence from settings where abortion is legal was 
supplemented by evidence from legally-restricted settings. Although indirectly relevant evidence 
may pose a threat to our confidence in a review finding (see CERQual approach in Lewin et al), we 
decided there could be important insights into women’s self-management of abortions at home 
from experiences in legally-restricted settings. This decision also increased the geographical spread 
of the included studies.  
Studies from settings where abortion is legal had to meet four criteria for inclusion: qualitative 
methodology, first trimester (<12 weeks) medical abortion (mifepristone and misoprostol or 
misoprostol-only), a shift to a less medicalized process as outlined in introduction, and data specific 
to self-management.  We included studies using qualitative methods for data collection and analysis 
as well as mixed-methods studies, provided the qualitative component met the above criteria. 
Studies from settings where abortion is legally restricted often did not specify the stage of pregnancy 
and frequently drew from experiences of informal care networks that may or may not have included 
health professionals. Inclusion of such studies was based therefore on qualitative 
design/method/analysis, and on reporting data pertaining specifically to the experience of managing 
an abortion at home and/or administering the medication without the presence of a healthcare 
professional. Studies that reported on general experiences of abortion without data on some 
dimension of self-management were excluded. 
Colleagues with expertise in abortion research (see acknowledgements) reviewed our list of included 
studies to help ensure important studies were not missed. One article in press was identified and 
included.  Of the studies meeting our inclusion criteria, five were in Portuguese and the remainder 
were in English. 
Data extraction and management 
For data extraction, we developed an initial framework organized around four areas: a) technical 
knowledge/comprehension/communication, b) motivations/acceptability of home use (attitudinal 
aspects), c) process/logistics/steps/feasibility, d) subjective experience/feelings/inter-personal 
context (including provider views of women's experiences). All four authors independently extracted 
data from five studies. After discussion and consensus on the data extraction framework and 
approach, MW extracted the remaining data.  
Data synthesis and CERQual 
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We synthesised data using thematic analysis, one of several approaches recommended by the 
Cochrane Qualitative Review Methods Group. [15]. After data extraction, MW and CC identified four 
key thematic areas and each took data from two thematic areas and drafted initial review findings. 
These were then discussed and refined, with a focus on clarifying review findings, supporting them 
with data and distinguishing them from each other. A second round of synthesis resulted in grouping 
review findings related to “issues of choice and control” as a fifth key thematic area. MW drafted a 
narrative that expanded on these key review findings and all authors revised the final synthesis.  
In cases where local contextual factors, such as legality of abortion, affected the review finding, we 
make note of this in the review finding. When specific local context is not mentioned in the review 
finding, it is because we believe the review finding is substantially similar across settings. 
We applied the GRADE-CERQual (Confidence of the Evidence from Reviews of Qualitative Research) 
to reach an overall assessment of confidence of either high, moderate, low or very low for each 
review finding (a summary of our review findings, including CERQual assessments, can be found at: 
www.cerqual.org. Note that CERQual is not an approach for assessing quality of individual studies or 
the quality of the overall synthesis. [14] It is a process for making judgements about our confidence 
in each individual review finding.  
Review Findings 
A total of 36 studies met our inclusion criteria (, 1). Nineteen (19) studies were conducted in settings 
where abortion is legalized, 14 studies in legally-restricted settings, and three studies were multi-
country studies with evidence from legal and legally-restricted settings. In legal settings, we found 
that the older studies described more medicalized approaches that required women to remain in 
clinic for four hours following misoprostol administration. [16] [17]. Shifts to less medicalized care in 
the more recent studies took the following forms: administering the misoprostol to women at the 
second appointment but then sending them home to abort [18-20] [4], giving women misoprostol at 
the second appointment but allowing them to self-administer it at home [18] [21], giving women 
misoprostol at the first appointment to be self-administered at home [19] [22-27], and giving 
women both mifepristone and misoprostol at the first appointment to be taken at home. [27] [28]. 
The studies from legal settings that reported misoprostol-only abortions reported self-
administration at home. [29] [30]. In the review findings we use self-administration when it pertains 
to taking the medication at home without direct medical supervision. When the review finding is not 
specific to taking the medication, but about other or more general aspects of the abortion process, 
we use the term self-management.  
[INSERT TABLE 1 AROUND HERE] 
General perceptions of self-management of medical abortion 
Providers were generally approving of the concept of self-management, including self-administration 
if initiation of medical abortion was supported by trained providers, and they believed that it could 
be done feasibly, effectively and safely. [16-19,25,27-32].  Even in restricted contexts, some offered 
support for women self-administering, by providing clinical advice and counselling and noting likely 
sources of the drug. Providers were not, however, generally supportive of over-the-counter access 
to medical abortion drugs. [33-36]. Self-management and self-administration allowed providers in 
restricted contexts to distance themselves legally from the abortion. [37] [38]. Providers in legal 
contexts could accomplish a similar kind of distancing on moral grounds. [17]. 
5 
 
Women were also generally approving of the concept of self-management.  They often reported 
some degree of anxiety at the beginning of the process but reported relief at the end and a strong 
sense of satisfaction with the choice to self-manage. [19] [20] [22] [23] [29]. In some contexts, the 
use of misoprostol at home for early medical abortion falls within existing interpretive frameworks 
and practices (such as “menstrual regulation” (Bangladesh) and was understood as one of many 
treatments for local illness categories referring to missed menstrual periods (e.g. “late menses” in 
Brazil). [32] [35] [36] [39]. Women in settings where there is little formal public information about 
abortion (whether in legal or legally-restricted settings), can sometimes be confused about the 
distinction between misoprostol for medical abortion, emergency contraception and oral 
contraceptives. [36] [38]. 
Women's perceptions of the acceptability of self-management without in-person contact with health 
professionals depended on: the standard of care and their prior experiences with medical abortion, 
local notions of professional medical hierarchy, abortion taboos and stigma, and perceptions around 
the strength, danger and complexity of the drugs. [20] [32] [40] [41].  
Providers’ perceptions about which healthcare workers should be able to provide medical abortion 
drugs to women for self-administration varied and depended on: perceptions of the strength of the 
drugs and hence the expertise in anatomy and physiology needed to explain their full effects; a 
provider’s training in appropriate counselling for abortion; a provider’s knowledge of abortion-
friendly emergency departments to refer women to in the case of complications; and the client’s 
experience, and therefore trust, of different healthcare workers. [16,33,42]. 
Preparation for self-management 
In preparing for self-management of medical abortion, women reported anxiety, uncertainty, or 
ambivalence, sometimes to do with the decision to terminate the pregnancy, but more often in 
relation to the process and experience of the medical abortion. [19,20,22,23,29,39,43,44]. Effective 
counselling by trained providers during the first step of medical abortion that offered women a 
sense of confidence, being prepared, having a choice, and being in control, was important in building 
the acceptability of self-management among women. [17,22-24,44]. Women and providers both felt 
that critical aspects of the educational component of counselling included preparing women for 
possible side effects and complications.  Critical psychosocial components of counselling included: 
preparing women for the variability in individual women's physical experiences of medical abortion; 
the practical and physical difficulties of managing the expulsion process at home; and the fact that 
most women reported anxiety during the beginning of the medical abortion process but relief at its 
completion. [20,22,23,30,33,36]. Providing adequate counselling in the context of health facilities 
was, however, seen as time consuming for health professionals and written materials for patients 
were reported to be underutilized. [19,22,29,33,34].  
We also derived a number of insights from evidence in both restricted and legal contexts where 
women self-administer misoprostol through informal networks. Women seek advice from a range of 
sources: friends, family, older women, websites, hotlines, pharmacists, informal sellers and 
sometimes even GPs without expertise in abortion. However, the information they receive can be 
inconsistent and/or inadequate and can lead to: variability in dosage, route and intervals; women 
not knowing what to expect; not trusting the quality of the medication; not knowing the duration of 
the process; being afraid of dying; and not knowing in which situations to seek help. Help may be 
sought prematurely when bleeding begins for fear of haemorrhage, or it can be dangerously delayed 
resulting in complications that require tertiary level care. [21,27,30,31,36,37,39,41,44-49]. Recent 
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studies indicate that women in settings where abortion is legally-restricted can access dependable 
and clear information from reputable hotlines and websites, when available. [40,44].  
Logistical considerations  
Women were drawn to self-management including self-administration for a number of practical 
reasons including lower costs, ease of scheduling, reduced transportation needs, ability to manage 
stigma, and being able to terminate the pregnancy earlier. In general, women found efforts to 
reduce the logistical demands of medical abortion via telemedicine and website and hotline-based 
forms of counselling to be acceptable and to support privacy and de-stigmatisation. A few women, 
however, noted that they preferred more direct engagement with trained providers and the clinic 
context for similar reasons of privacy, ease and security. [18,20,25,30,37,40,42,44,50].  
Women who self-administered or would have liked to, valued the sense of control over the process, 
the timing of the onset of symptoms (in contrast to being anxious about symptoms starting on the 
way home from clinic), the ability to plan for bleeding around work and caring duties, and the ability 
to maximize comfort and make arrangements to be accompanied or, in fewer cases, choose to be 
alone with telephone support. [4,21-23,44]. When women were counselled by trained providers in 
the self-administration of misoprostol, providers trusted women’s ability to comply with dosage and 
timing requirements, women felt confident and reported uncomplicated abortions for the most part, 
and women called hotlines or consulted providers when the abortion process did not proceed as 
expected. [19,21,26,28,32-34,37,44,50].  
Although less commonly reported, concerns regarding the process of prescribing misoprostol for 
self-administration at home included not keeping oral misoprostol in one’s cheek long enough, 
developing abrasions, feeling nauseous from the taste of misoprostol, taking the misoprostol earlier 
than indicated, having difficulty administering the misoprostol vaginally and worrying about whether 
the medication was taken properly. [19] [29] [44]. There were also reports of misunderstandings and 
inconsistencies regarding the prescription and use of painkillers as part of the counselling for home 
use, including staff not providing pain medication, or women not taking them because of fear that it 
would stop the abortion process or the belief that the misoprostol pill contained its own painkiller. 
[18] [44]. 
Issues of choice and control  
Numerous social, economic and cultural factors, including concerns around privacy, cost, 
convenience, comfort and perceptions of medical care, affected the degree to which self-
administration of misoprostol was the preferred method of abortion for individual women.  Women 
expressed a desire to be able to choose the method of abortion that fit their context and 
circumstances. [20,29,41,42,44]. Having the choice to self-administer medication at home (versus 
having it in clinic), may be an important element of acceptability of medical abortion for women. 
[4,20,23,25,43].  
There were some concerns among women and providers, with respect to women's autonomy over 
their sexual and reproductive health decision-making, around the potential unintended 
consequences of increasing access to medical abortion through self-management and self-
administration.  Specifically, there were concerns that increased access to misoprostol, especially via 
pharmacists, with or without prescription, could increase men's, and mothers’ involvement in and 
control over abortion—either in a restrictive or a coercive fashion—and increase pressure for sex-
selective abortions. [26,30,33,42,49]. Again, while providers were optimistic that having the choice 
to self-administer could help increase access to abortion services for younger women whose age 
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often represented a barrier to access, some older women were concerned that increasing access 
would incentivise the use of abortion as a form of routine family planning for younger women. [22] 
[42]. 
Pharmacists were commonly drawn upon for information about pregnancy termination, but in 
contexts where abortion is legally restricted, pharmacists feared legal repercussions. Nonetheless, 
some took the risk and counselled women (often based on inadequate training and knowledge) 
about how to take misoprostol and what to expect, and in some cases even distributed misoprostol. 
[28,33,36,47]. There was distrust, however, among women and providers in pharmacists’ ability to 
properly counsel and administer medical abortion. Distrust arose from a perception of pharmacists 
as business people, as not holding adequate knowledge, and of being incapable or uninterested in 
providing follow-up in the case of complications. Distrust also stemmed from a sense that 
pharmacies and pharmacists were poorly regulated and controlled, thus augmenting the potential 
for unequal treatment options/prices for clients and counterfeit or poor quality/”weak” drugs. 
[19,20,28,32,33,36,42,47].  
Cost was an important factor shaping choices for self-management from the perspective of both 
women themselves and physicians and pharmacists. [18,28,30,31]. To save costs, some women went 
directly to a pharmacist without going to the physician first, and some chose to use only misoprostol 
(instead of misoprostol and mifepristone). [28, 30]. Pharmacists also reported making judgments 
about the purchasing power of their clients when recommending treatments to end pregnancy. [28]  
Meaning and experience  
The evidence showed that self-management allowed for a new range of meanings and experiences 
of abortion to emerge, increasing the acceptability of self-management.  These included the sense 
that it is more “natural” (more like a period or miscarriage), less about “killing”, less 
clinical/medicalised, allows one to be more “in control”, and allows for grief and other alternative 
moral interpretations and emotional experiences. [17,22-24,35,39,43,44].  
Self-management with self-administration also increased the opportunities for partners to be 
involved in supporting women through their medical abortions at home. However, both men and 
women expressed a desire for more counselling of partners about the process of medical abortion 
itself (e.g., what to expect with respect to pain, bleeding, side effects, length of the process) and 
what role they could play in supporting their partners. [24,26,27,40,44]. 
Having an abortion at home also meant greater direct contact with the products of conception as 
they are expelled and the evidence describes different levels of comfort dealing with them. Many 
were curious to see, some worried about what they would see, while others held the products of 
conception and inspected them more closely. Comfort with seeing these products depended on the 
individual as well as the cultural context. [17,20,23].   
 
Discussion  
Consistent with quantitative findings, [2] while most women describing their experiences with 
medical abortion in legal settings reported a strong sense of satisfaction with the choice to self-
manage, some expressed a desire for more medicalized care. Reasons included insecurities around 
proper administration of the medication, convenience, ability to manage complications, having 
support during the process, and maintaining privacy. The concept of “privacy” is a good example of 
the cultural specificity of some of these review findings. Similarly, “convenience” depends on how 
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the woman perceives the differences between her home and the clinic and these differences affect 
what seems most comfortable. For example, women and partners in Sweden reported valuing the 
choice to be home for the privacy, quiet, security and comfort it offered. [23] [24]. In a study of rural 
Indian women, however, even though being able to stay home could help maintain privacy (by 
preventing neighbours from seeing one go back and forth to hospital), most were opposed to taking 
misoprostol at home. They were concerned about not having the appropriate facilities, having no 
place to lie down, and the added burden of having to continue daily household chores for others in 
the family. [42]. Where possible, women should have the ability to choose different options for 
medical abortion and different degrees of self-management [1] as suits their setting and 
preferences.   
Synthesizing the experiences and perceptions around self-management in legally-restricted and 
unrestricted contexts demonstrated the key role informed counselling plays in ensuring both 
medical abortion’s proper use and women’s confidence.  Harm-reduction programmes have shown 
that providing adequate counselling is possible even in restricted contexts. [34, 50]. One interesting 
intervention in a legally-restricted setting took the approach that it was a health professional’s duty 
to tell women what their options are when faced with an unwanted pregnancy, and one of those 
options is to obtain misoprostol on the black market. [34]. The intervention included: consulting 
women on the availability of misoprostol on the black market, what to look out for when buying the 
medication, how to take the medication if they decided on that option, and scheduled a follow-up 
appointment. As counselling programmes in restricted settings have to prepare women for self-
management including self-administration (and frequently self-assessment), their approaches 
provide important insights for programme planners in legal settings working towards less 
medicalized abortion services. Based on evidence from legal and legally-restricted settings, our 
recommendation is that counselling and support to women considering self-management should 
include instructions and information regarding: 1) the fact that medical abortion should not be 
confused with emergency or oral contraception, 2) how to take the medication, including dosage, 
timing and how to actually administer the drug vaginally or orally, 3) what to expect after taking the 
medication, including the wide degree of variability of physical experiences of medical abortion as 
well as possible psychological experiences, 4) possible side effects and how to deal with these, 5) 
how to plan for the management of the expulsion process at home, 6) if and when to take pain 
killers, which painkillers to take, and where these can be obtained, and 7) how to recognise in which 
situations to seek help.  
With regards to managing the expulsion process, one guideline recommends that women receive 
guidance on what they can do with the products of conception and one option should be bringing 
the tissue back to the health centre for disposal. [51]. Dealing with the products of conception is an 
important experiential element of self-management of medical abortion, and one that is not well 
reported on in the qualitative literature. This may be a sensitive area for women, and therefore 
research designs should include space and time for researchers to build rapport and trust with their 
participants in order to explore this issue. Understanding women’s practices, and preferences 
regarding the expelled products is important especially as this is likely to vary not just culturally but 
also in relation to gestational age of the foetus.  These differences may make it more or less easy for 
women to describe the appearance of their bleeding and identify the passing of the foetus, as well 
as shape their preferences for what to do with the products of conception. 
Counselling, whether in restricted or unrestricted contexts, should also be provided for the person(s) 
who may be supporting the woman during her abortion at home, in particular, for women’s 
partners.  An important future research question is how the expectations, levels of comfort and 
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confidence of partners or other supporters, shape the woman’s experience and the process of self-
management. This question may be particularly important in contexts where men’s anxiety about 
the levels of pain or bleeding cause them to insist that their partners seek healthcare. However, 
considerations around partners’ needs also must be balanced against the possibility that men’s 
involvement could lead to restrictions or coercion in relation to abortion. A Brazilian study described 
a criminal case where a man had inserted misoprostol into his pregnant partner’s vagina during sex 
without her knowing. [47] On the other hand, in restricted contexts, men often play an important 
role in procuring the misoprostol for their partners from the pharmacy since they are likely to be 
asked fewer questions by pharmacists (the medication is also prescribed for ulcers – more common 
among men). 
As the standard of care has moved significantly towards self-management of not only misoprostol 
but also of mifepristone, [52] more qualitative research is needed on the experience of these less 
medicalized forms of service provision. For example, a qualitative study of innovations in places such 
as Australia where combination packs of mifepristone and misoprostol are available to be prescribed 
by physicians and dispensed at pharmacies [53] would add to this limited body of evidence. [27,28].   
Furthermore, in settings where women may not be aware of medical abortion, they may or may not 
be offered it as a choice, depending on local providers’ own ideas regarding eligibility, 
appropriateness and risk. Understanding these implicit and explicit reasons for giving some women 
the option to administer at home, and others not, is important because individual practitioners may 
be assessing “eligibility” by their own implicit criteria, in turn limiting the options for certain women 
(for example, rural women).  
Limitations of the Review 
The main limitations of this review is the variability of models of care for medical abortion across 
different settings. Another limitation is the fact that self-management was rarely the primary topic 
of interest of the included studies and as such, the data pertaining to self-management was 
relatively thin. This could be because issues related to self-management were not explored with 
research participants as thoroughly as they could have been, or because they were not reported on 
as much as they could have been. It was also difficult to tell from the qualitative literature whether 
differences in experience were related to different models of self-management, and how access to 
mifepristone-misoprostol abortion, vs. misoprostol-only abortion might have influenced the 
experience.  
Conclusion 
The overall acceptability and feasibility of self-management of medical abortion is supported by the 
qualitative evidence. However, in conducting this qualitative evidence synthesis we have identified 
that, from a global perspective, more qualitative research on self-management is needed. Research 
is needed on all aspects of the self-management process (e.g., self-administration, managing 
expulsion, assessing termination, following up if needed, etc.), as services move to less-medicalized 
programmes. Our review findings highlight what, according to current qualitative evidence, have 
been the shifts towards less medicalized medical abortion and the experiences, preferences and 
concerns arising from these shifts. It makes the point that evidence from legal and legally-restricted 
settings provide relevant insights in this regard.  
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